SectorBiological Technology
Established Date--
Listing Date15/11/2022
ExchangeNASDAQ Stock Exchange
Full-time Employees74
Fiscal Year Ends31/12
Security TypeCommon stock
Office address480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472
Business
IntroductionAcrivon Therapeutics, Inc., was incorporated in Delaware in March 2018. The Company, a clinical-stage biopharmaceutical company developing precise oncology drugs, utilizes its proprietary proteomics-based Patient Respondent Identification Platform to match them to patients whose tumor predictions are sensitive to each specific drug. The company develops its pipeline of oncology drug candidates by using its proprietary precision drug platform AP3. (The company's AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics to identify patients most likely to benefit from the company's drug candidates, which the company calls patient responders).
